Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Isatuximab in combination to treat relapsed/refractory MM

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 17.06.18
Views: 1757

Dr Joseph Mikhael - Chief Medical Officer of the International Myeloma Foundation

Dr Mikhael speaks with ecancer at EHA 23 about a phase Ib study of isatuximab, a CD38 targeted therapy, in combination with pomalidomide and dexamethasone to treat relapsed multiple myeloma.

He outlines the dose selection, and highlights the shorter infusion time of isatuximab compared to other CD38 molecules.

Patients experienced a 65% response rate with PFS approaching 18 months, and Dr Mikhael introduces recruitment for further trials of the combination.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Donate to ecancer

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation